Navigation Links
Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Date:4/24/2012

es the need for more effective treatments in metastatic RCC."

The FDA's Fast Track program is designed to facilitate the development and expedite the review of new drugs for the treatment of serious or life-threatening diseases with the potential to address unmet medical needs. Fast Track designation allows for the review timeline to be truncated to six months compared to the traditional 12 months.

The Phase 3 ADAPT study is a randomized, multicenter, open-label study of AGS-003 in combination with sunitinib compared to sunitinib plus placebo. Argos plans to enroll approximately 450 mRCC patients at approximately 100 clinical sites in North America and Europe. The primary endpoint for the ADAPT study is overall survival. Additional endpoints include overall response, immune response, progression-free survival and safety.

Regarding the Phase 2 clinical study, 21 patients with newly diagnosed metastatic clear cell RCC were enrolled. Treatment consisted of six-week cycles of sunitinib, four weeks on and two weeks off, plus AGS-003, which was administered as an intradermal injection every three weeks for five doses, and then every 12 weeks until progression in combination with sunitinib. Results presented during the 2012 ASCO Genitourinary Cancers Symposium indicated that the median progression-free survival in patients with newly diagnosed, unfavorable risk mRCC was 11.2 months and estimated Kaplan-Meier median overall survival was 29.3 months in this study, based upon follow-up through January 2012. In addition, AGS-003 was well tolerated in combination with sunitinib, with no immunotherapy related serious adverse events observed.   

About the Arcelis™ Technology

Arcelis is Argos's proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies. This platform is based on optimizing a patient´s own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune respon
'/>"/>

SOURCE Argos Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
2. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
3. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
4. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
5. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
6. Argos Therapeutics Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
7. Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering
8. Argos Therapeutics Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 2013   National Community Pharmacists Association (NCPA) ... MBA issued the following statement today regarding a ... D "preferred pharmacy" drug plans , which often ... lowest advertised co-payments: (Logo:  http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ) ... MedPAC , 16 U.S. Senators and ...
(Date:5/20/2013)... 20, 2013  Hill-Rom Holdings, Inc. (NYSE: ... presentation at the 38 th Annual Deutsche Bank ... on May 30, 2013, at 1:30 p.m. EDT. ... are invited to listen to the live discussion via ... it directly at http://www.media-server.com/m/p/f7bj3q84 . A recorded replay ...
(Date:5/20/2013)... May 20, 2013 Sequent Medical, Inc. announced ... SL ("Single Layer") family of WEB ® Aneurysm ... these new models in select neurovascular centers in Europe.  ... navigability that will enable physicians to treat a broader ... The SL configurations are made possible by further advancement ...
Breaking Medicine Technology:Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 2Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 3Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 4Sequent Medical, Inc. Launches New SL Family of WEB Aneurysm Embolization Devices 2
... , , , , PORTSMOUTH, Va., Dec. ... away over $6,000,000 worth of its new LifeGuard30(TM) medical ... afford to buy them as well as to charitable and non-profit ... stores and displays vital patient information at the scene of a ...
... , , , , , , SEATTLE, Dec. ... today that on December 24, 2009, CTI,s Board of Directors (the ... "Rights Plan") in which one preferred stock purchase right will be ... business on January 7, 2010. Initially, the rights are not exercisable, ...
Cached Medicine Technology:ViVre Medical Announces $6,000,000 Gift 2ViVre Medical Announces $6,000,000 Gift 3Cell Therapeutics, Inc. Adopts Shareholder Rights Plan 2Cell Therapeutics, Inc. Adopts Shareholder Rights Plan 3Cell Therapeutics, Inc. Adopts Shareholder Rights Plan 4
(Date:5/20/2013)... 20, 2013 Fastcare Miami Beach clinic ... (UTI) within its first symptoms, as if not treated, it ... more serious infection. Although a urinary tract infection in itself ... to serious kidney infection called pyelonephritis. Women seem to have ... up to the same percentage as women after the age ...
(Date:5/20/2013)... In order to prepare for the long ... from DrSmartphoneMD launched an article series to raise awareness about ... series launched with the precautions that need to be ... program are not one of the 3.5 million cases of ... 90% of all skin cancer cases are associated with exposure ...
(Date:5/20/2013)... May 20, 2013 Eben ... to the public creating a frenzy among business ... this elite business training. WealthSpringMarketing.com's Tiffany Hendricks has ... as an exclusive bonus. , "Eben Pagan is ... business training to individuals serious about success," reports ...
(Date:5/20/2013)... 20, 2013 Parker Waichman LLP, a ... victims injured by defective drugs, has filed a lawsuit ... that use of the diabetes drug medication Actos ... on April 30, 2013, in the U.S. District Court ... where it is one of thousands of cases pending ...
(Date:5/20/2013)... 2013 Leading facial plastic surgeon and ENT ... a “Top Doc” in the field of Otolaryngology in the ... The Palm Beacher magazine, one of Palm Beach County’s leading ... the May/June 2013 issue, including 70 of the very best ... events, things to do, health and fitness, people to watch, ...
Breaking Medicine News(10 mins):Health News:Fastcare Advises on How to Prevent a UTI 2Health News:Combat Skin Cancer In Summer Months 2Health News:Eben Pagan's Accelerate: Review and Bonus Released By WealthSpringMarketing.com 2Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2Health News:Dr. Schwartz Named “Top Doc” by The Palm Beacher Magazine 2
... working with an international team of health and ... to provide long-term weather forecasts to medical officials ... The forecasts will enable local health providers to ... disease, which is correlated with dry and dusty ...
... 19 Medipacs, Inc., a Tucson based drug,delivery device company ... Invest Southwest Capital Conference to be held in Scottsdale,AZ on ... One of only 12 companies to present at ... of high-tech fields. "Generally,speaking, (the businesses) have to be highly ...
... consumers filed a proposed,nationwide class-action lawsuit earlier this week ... BAY), alleging the pharmaceutical giant,skirted FDA requirements in marketing ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080317/AQM144LOGO ) , ... markets two of its over-the-counter products --,Bayer Aspirin with ...
... A. Hoke,has joined the Sisters of Charity Health System ... for the Cleveland-,based organization and its 20 health and ... announcement was made by Sisters of Charity Health System,President ... "We are pleased to ...
... Nov. 19 Healthcare Management Systems,Inc.(R) (HMS) presented the 4th Annual ... the healthcare field. The awards were,presented Friday, October 17, during the ... Awards were presented to the following nominees: , ... Respiratory Care Center, Inc., Mt.,Vernon, Ky. , ...
... 19 Have you ever asked yourself, "What in the world ... safe to give your puppy a leftover turkey drumstick - or ... , , To address these and ... (AVMA) today launched a new podcast series, "Chew on This," dedicated ...
Cached Medicine News:Health News:UCAR weather forecasts aim to reduce African meningitis epidemics 2Health News:UCAR weather forecasts aim to reduce African meningitis epidemics 3Health News:Medipacs Chosen to Present at Invest Southwest Capital Conference 2Health News:Hagens Berman Files Class Action Against Bayer Healthcare Over Misleading Marketing Campaign 2Health News:Hagens Berman Files Class Action Against Bayer Healthcare Over Misleading Marketing Campaign 3Health News:Wendy Hoke Joins the Sisters of Charity Health System as Communications Officer 2Health News:Wendy Hoke Joins the Sisters of Charity Health System as Communications Officer 3Health News:HMS Presents 4th Annual Heroes of Healthcare Awards 2Health News:HMS Presents 4th Annual Heroes of Healthcare Awards 3Health News:AVMA Launches 'Chew on This' Podcast Series on Food Safety 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: